New strategies with anti-IgE in allergic diseases

World Allergy Organization Journal

Volumn 7, Issue 1, 2014, Pages

  Holgate, Stephen T ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Allergy; Anti IgE monoclonal antibody; Asthma; Comorbidity; Omalizumab

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB;

AIRWAY REMODELING; ALLERGIC ASTHMA; ALLERGIC DISEASE; COMORBIDITY; DRUG POTENCY; GENE TARGETING; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY;

EID: 84910669251     PISSN: None     EISSN: 19394551     Source Type: Journal    
DOI: 10.1186/1939-4551-7-17     Document Type: Review

References (27)

1. Carl Prausnitz: a personal memoir. AW Frankland, J Allergy Clin Immunol 2004 114 700 704 10.1016/j.jaci.2004.06.040 15356577
2. Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity and E-globulin antibody. K Ishizaka, T Ishizaka, M Hornbrook, J Immunol 1966 97 840 853 4163008
3. Molecular and cellular mechanisms of allergic disease. DH Broide, J Allergy Clin Immunol 2001 108 2 Suppl 65 S71 11498675
4. An investigation into IgE-facilitated allergen recognition and presentation by human dendritic cells. IK Sharquie, A Al-Ghouleh, P Fitton, MR Clark, KL Armour, HF Sewell, F Shakib, AM Ghaemmaghami, BMC Immunol 2013 14 54 10.1186/1471-2172-14-54 24330349
5. Interaction of IgE with its high-affinity receptor. Structural basis and requirements for effective cross-linking. B Baird, RJ Shopes, VT Oi, J Erickson, P Kane, D Holowka, Int Arch Allergy Appl Immunol 1989 88 23 28 10.1159/000234742 2523358
6. Therapeutic potential of anti-IgE antibodies. C Heusser, P Jardieu, Curr Opin Immunol 1997 9 805 813 10.1016/S0952-7915(97)80182-3 9492982
7. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Corne, R Djukanovic, L Thomas, J Warner, L Botta, B Grandordy, D Gygax, C Heusser, F Patalano, W Richardson, E Kilchherr, T Staehelin, F Davis, W Gordon, L Sun, R Liou, G Wang, TW Chang, S Holgate, J Clin Invest 1997 99 879 887 10.1172/JCI119252 9062345
8. Omalizumab. S Easthope, B Jarvis, Drugs 2001 61 253 260 10.2165/00003495-200161020-00008 11270941
9. Omalizumab for asthma in adults and children. R Normansell, S Walker, SJ Milan, EH Walters, P Nair, Cochrane Database Syst Rev 2014 1 D003559 24414989
10. The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. JD Campbell, RB McQueen, A Briggs, Ann Am Thorac Soc 2014 11 Suppl 2 105 S111 24559022
11. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. A Long, A Rahmaoui, KJ Rothman, E Guinan, M Eisner, MS Bradley, C Iribarren, H Chen, G Carrigan, K Rosén, S Szefler, J Allergy Clin Immunol 2014 pii: S0091-6749 14 00204-8 [Epub ahead of print]
12. Omalizumab: Practical considerations regarding the risk of anaphylaxis. HL Kim, R Leigh, A Becker, Allergy Asthma Clin Immunol 2010 6 32 10.1186/1710-1492-6-32 21129189
13. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. J Bousquet, K Rabe, M Humbert, KF Chung, W Berger, H Fox, G Ayre, H Chen, K Thomas, M Blogg, S Holgate, Respir Med 2007 101 1483 1492 10.1016/j.rmed.2007.01.011 17339107
14. Loss of receptors and IgE in vivo during treatment with anti-IgE antibody. DJ MacGlashan, Allergy Clin Immunol 2004 114 1472 1474 10.1016/j.jaci.2004.07.064
15. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. JT Schroeder, AP Bieneman, KL Chichester, RG Hamilton, H Xiao, SS Saini, MC Liu, J Allergy Clin Immunol 2010 125 896 901 10.1016/j.jaci.2009.10.021 20132969
16. Allergy. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. EL van Rensen, CE Evertse, WA van Schadewijk, S van Wijngaarden, G Ayre, T Mauad, PS Hiemstra, PJ Sterk, KF Rabe, Allergy 2009 64 72 80 10.1111/j.1398-9995.2008.01881.x 19076931
17. Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma. L Prieto, V Gutiérrez, C Colás, A Tabar, C Pérez-Francés, L Bruno, S Uixera, Int Arch Allergy Immunol 2006 139 122 131 10.1159/000090387 16374021
18. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. MH Lafeuille, J Dean, J Zhang, MS Duh, B Gorsh, P Lefebvre, Ann Allergy Asthma Immunol 2012 109 59 64 10.1016/j.anai.2012.04.015 22727159
19. Arch Dis Child. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. M Brodlie, MC McKean, S Moss, DA Spencer, Arch Dis Child 2012 97 604 609 10.1136/archdischild-2011-301570 22685051
20. Omalizumab decreases exacerbation and allows a step down in daily inhaled corticosteroid dose in adults and children with moderate-to-severe asthma. NC Thomson, Evid Based Med 2014 doi: 10.1136/eb-2014-101759. [Epub ahead of print]
21. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. WW Busse, WJ Morgan, PJ Gergen, HE Mitchell, JE Gern, AH Liu, RS Gruchalla, M Kattan, SJ Teach, JA Pongracic, JF Chmiel, SF Steinbach, A Calatroni, A Togias, KM Thompson, SJ Szefler, CA Sorkness, N Engl J Med 2011 364 1005 1015 10.1056/NEJMoa1009705 21410369
22. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. M Hoshino, J Ohtawa, Respiration 2012 83 520 528 10.1159/000334701 22236804
23. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. AM Riccio, RW Dal Negro, C Micheletto, L De Ferrari, C Folli, A Chiappori, GW Canonica, Int J Immunopathol Pharmacol 2012 25 475 484 22697079
24. Anti-IgE; Emerging opportunities for Omalizumab. KS Babu, R Polosa, JB Morjaria, Expert Opin Biol Ther 2013 13 765 777 10.1517/14712598.2013.782391 23517576
25. Omalizumab for the treatment of chronic idiopathic or spontaneous urticarial. M Maurer, K Rosén, HJ Hsieh, S Saini, C Grattan, A Gimenéz-Arnau, S Agarwal, R Doyle, J Canvin, A Kaplan, T Casale, N Engl J Med 2013 368 924 935 10.1056/NEJMoa1215372 23432142
26. QGE031 high affinity anti-IgE: tolerability, safety, pharmacokinetics and pharmacodynamics in atopic subjects. J Arm, 2013 September 10th; ERS abstract 850518; Session 363
27. Emerging treatments for pemphigoid diseases. RJ Ludwig, K Kalies, J Köhl, D Zillikens, E Schmidt, Trends Mol Med 2013 19 501 512 10.1016/j.molmed.2013.06.003 23831338